Drugs / MRT-2359
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05546268 | Oct 2022 → May 2026 overdue | diffuse large B-cell lymphoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, prostate cancer +1 | Monte Rosa Therapeutics, Inc | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Monte Rosa Therapeutics, Inc | Results Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates monterosatx.com ↗
Presented positive interim data from the Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide showing 100% PSA response rate in metastatic castration-resistant prostate cancer (mCRPC) patients with AR mutations |
| 2026-02-24 | Monte Rosa Therapeutics, Inc | Results Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU) monterosatx.com ↗
Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRT-2359 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05546268 ↗ |
| Modality | Other / unclassified | “a GSPT1 molecular glue degrader MRT-2359” NCT05546268 ↗ |
| Route | Oral | “Orally administered tablets of MRT-2359.” NCT05546268 ↗ |
| Target | GSPT1 | “a GSPT1 molecular glue degrader MRT-2359” NCT05546268 ↗ |